Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Seagen

    Client Virtual Booth

    SEAGEN

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Seagen
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    21717 30th Drive S.E., Building 3 Bothell, WA 98021
    Telephone
    Telephone
    1-425-527-4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.seagen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/seagen
    Twitter
    Twitter
    https://twitter.com/SeattleGenetics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Pfizer to press pause on large M&A deals, CEO says
    Pfizer to press pause on large M&A deals, CEO says

    https://www.fiercepharma.com/pharma/pfizer-ceo-says-company-needs-take-breathing-period-after-massive-ma-stretch

    Fraiser Kansteiner FIERCE PHARMA
    11 Jun 2024
    Share Share
    Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial
    Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial

    https://endpts.com/asco24-pfizer-shares-the-adc-data-that-convinced-it-to-start-a-phase-3-lung-cancer-trial/

    Lei Lei Wu ENDPTS
    24 May 2024
    Share Share
    Pfizer telegraphs another round of Seagen layoffs
    Pfizer telegraphs another round of Seagen layoffs

    https://www.fiercepharma.com/pharma/pfizer-puts-74-seagen-jobs-chop-it-continues-consolidate-newly-combined-cancer-organization

    Fraiser Kansteiner FIERCE PHARMA
    09 May 2024
    Share Share
    Pfizer lifts profit view on cost cuts, demand for COVID products
    Pfizer lifts profit view on cost cuts, demand for COVID products

    https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-beats-profit-estimates-cost-cuts-rsv-vaccine-sales-2024-05-01/

    REUTERS
    02 May 2024
    Share Share
    Seagen’s former commercial chief joins the board at healthcare agency
    Seagen’s former commercial chief joins the board at healthcare agency

    https://endpts.com/seagens-former-commercial-chief-joins-the-board-at-healthcare-agency-minds-assembly/

    Beth Snyder Bulik ENDPTS
    22 Mar 2024
    Share Share
    Seagen patent invalidated in long-running Daiichi Sankyo spat
    Seagen patent invalidated in long-running Daiichi Sankyo spat

    https://www.fiercepharma.com/pharma/patent-authority-scratches-seagen-patent-daiichi-sankyo-win-after-long-running-enhertu

    FIERCE PHARMA
    18 Jan 2024
    Share Share
    Patent Office Invalidates Seagen Patent in Dispute between Daiichi and Seagen
    Patent Office Invalidates Seagen Patent in Dispute between Daiichi and Seagen

    https://www.businesswire.com/news/home/20240116137394/en

    BUSINESSWIRE
    16 Jan 2024
    Share Share
    Pfizer's $43B buyout of ADC specialist Seagen is a done deal
    Pfizer's $43B buyout of ADC specialist Seagen is a done deal

    https://www.fiercepharma.com/pharma/done-deal-pfizer-completes-43b-acquisition-seagen-doubling-its-oncology-pipeline

    Kevin Dunleavy FIERCE PHARMA
    14 Dec 2023
    Share Share
    Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
    Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights

    https://www.reuters.com/markets/deals/pfizer-gets-ok-43-bln-seagen-deal-after-donating-cancer-drug-rights-2023-12-12/

    REUTERS
    13 Dec 2023
    Share Share
    ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
    ADCETRIS Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma

    https://www.businesswire.com/news/home/20231210494461/en

    BUSINESSWIRE
    10 Dec 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search